Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$58.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$58.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$57.76M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$58.43M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-69.82%
5Y Avg
-186.89%
Market Cap
$58.44M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$57.61M
Net Profit Margin
-1507600.00%
TTM Avg
-25517.85%
3Y Avg
-13465.42%
5Y Avg
-10648.78%
Market Cap
$57.01M
Net Profit Margin
-86687.50%
TTM Avg
-43373.76%
3Y Avg
-21686.88%
5Y Avg
-14457.92%
Market Cap
$59.18M
Net Profit Margin
-34.06%
TTM Avg
-499.05%
3Y Avg
-249.52%
5Y Avg
-166.35%
Market Cap
$60.02M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | 0.00% | 0.00% | -69.82% | -186.89% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Talphera, Inc. (TLPH)vs › | $57.61M | -1507600.00% | -25517.85% | -13465.42% | -10648.78% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | -86687.50% | -43373.76% | -21686.88% | -14457.92% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | -34.06% | -499.05% | -249.52% | -166.35% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | 0.00% | 0.00% | 0.00% | 0.00% |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | -1529.70% |
